[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"claudication-intermittent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:claudication-intermittent":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,77,100,122,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100301374","red-light-treatment-in-peripheral-artery-disease-100301374",false,"NCT03203239","Red Light Treatment in Peripheral Artery Disease","Vasodilatory Effects of Light on Peripheral Artery Disease","Inclusion Criteria:\n\n* Participants will be subjects between the ages of 18 and 85 who have been diagnosed with peripheral artery disease. Men and women will be recruited for participation. All ethnicities will be included in this study.\n\nDiagnosis of peripheral artery disease is defined as an Ankle Brachial index of \\\u003C0.9 or greater than 1.1 either at rest or during treadmill exercise.\n\nExclusion Criteria:\n\n* Exclusionary criteria include age under 18 years and over 85 years, those who are unable to understand the consent process , those who cannot read or speak English, active pregnancy, hypersensitivity to perflutren contrast agents, pulmonary hypertension, active illicit drug use, untreated blood pressure over 160\u002F95, sickle cell disease, or a history of intracardiac shunt. Additional exclusion criteria neurological diseases such as spinal stenosis, unspecified pain disorders, and any uncontrolled medical conditions.","ALL","18 Years","85 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (\\\u003C.9 or \\>1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquisition of ultrasound images. 2 blood samples will be collected for measurement of nitric oxide metabolites.",[27,28,29],"Peripheral Artery Disease","Claudication, Intermittent","Vasodilation",[31,32,33],"red light","vasodilation","nitric oxide","RECRUITING","2026-04-27",{"date":37,"type":38},"2026-05-01","ACTUAL",{"date":40,"type":38},"2018-01-17",{"date":42,"type":21},"2028-12-31",{"name":44,"class":45},"University of Alabama at Birmingham","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100619091","expression-of-glp1-receptor-on-peripheral-blood-mononuclear-cells-in-advanced-peripheral-artery-disease-paving-the-way-for-glp1r-agonists-treatment-in-chronic-limb-threatening-ischemia-100619091","NCT07340112","Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening Ischemia","EXCEL-CLTI","Inclusion Criteria:\n\n* Patients aged 40 years or older\n* Documented Peripheral Artery Disease (PAD): Patients must fall into one of the two following severity groups:\n\n  1. Intermittent Claudication (IC) Group: Defined by a maximum walking distance limited by intermittent claudication, associated with an Ankle-Brachial Index (ABI) \\\u003C 0.9 at rest.\n  2. Chronic Limb-Threatening Ischemia (CLTI) Group: Defined by ischemic rest pain and\u002For tissue loss (ulcers or gangrene) persisting for at least 15 days, associated with a toe pressure or a transcutaneous oxygen tension (tcPO2) \\\u003C 30 mmHg, according to the 2024 ESC guidelines.\n\nExclusion Criteria:\n\n* Diabetes Mellitus: Diagnosis of Type 1 or Type 2 diabetes\n* Current Specific Pharmacotherapy: Ongoing treatment with SGLT2 inhibitors (SGLT2i) or GLP-1 receptor agonists (GLP-1RA).\n* Infection: Presence of sepsis or an active systemic infection.\n* Malignancy: Active cancer or hematologic malignancies.\n* Immunosuppression: History of organ transplantation or autoimmune diseases currently requiring immunosuppressive therapy.\n* Known chronic inflammatory diseases.\n* Advanced Renal Failure: End-stage renal disease requiring dialysis.","40 Years",{"count":56,"type":21},50,"OBSERVATIONAL","The goal of this observational study is to learn whether activation of the GLP-1 receptor could represent a therapeutic target by characterizing its expression and associated inflammatory mechanisms in patients with peripheral artery disease, according to disease severity, in adults with symptomatic lower-limb peripheral arterial disease.\n\nThe main questions it aims to answer are:\n\n* Is the level of GLP-1 receptor (GLP1R) expression on peripheral blood mononuclear cells (PBMC) different between patients with intermittent claudication (ischemia of effort) and those with chronic limb-threatening ischemia?\n* Is GLP1R expression associated with inflammatory and oxidative profiles of PBMC?\n* Can GLP-1 receptor agonists reverse inflammatory and oxidative alterations induced by plasma from patients with peripheral artery disease in endothelial cell cultures?\n* Are there specific plasma proteomic signatures associated with GLP1R overexpression?\n\nResearchers will compare patients with intermittent claudication to patients with chronic limb-threatening ischemia to see if disease severity is associated with differences in GLP1R expression, PBMC inflammatory\u002Foxidative phenotype, and plasma proteomic profiles.\n\nParticipants will:\n\n* Provide an additional blood sample (15 mL) collected during a routine, clinically indicated blood draw\n* Have PBMC isolated for measurement of GLP1R expression and assessment of inflammatory and oxidative markers\n* Have plasma analyzed for proteomic profiling and used in in-vitro endothelial cell experiments\n\nParticipation ends after completion of the blood sampling, and no additional procedures beyond standard clinical care are required.",[60,28,61],"Peripheral Arterial Disease (PAD)","Chronic Limb-Threatening Ischemia",[63,64,65,66],"Peripheral arterial disease","Chronic limb-threatening ischemia","GLP-1 receptor","Peripheral blood mononuclear cells (PBMC)","NOT_YET_RECRUITING","2026-01-05",{"date":70,"type":38},"2026-01-14",{"date":72,"type":21},"2026-06",{"date":74,"type":21},"2028-06",{"name":76,"class":45},"University Hospital, Strasbourg, France",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":18,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100519310","passive-calf-stretching-therapy-in-peripheral-artery-disease-100519310","NCT06041880","Passive Calf Stretching Therapy in Peripheral Artery Disease","To Stretch, Not Strain: Impact of Passive Stretching on Calf Muscle and Gait Mechanics in PAD","Inclusion Criteria:\n\n* Presence of PAD\n* Stable condition (PAD symptoms) for at least 3 months\n* Age 40-85\n* Men and women who are not pregnant or nursing\n\nExclusion Criteria:\n\n* Ischemic leg pain at rest; critical limb ischemia (ulceration or gangrene)\n* Any condition other than PAD that limits the ability to walk\n* Major surgery or lower extremity revascularization surgery in the past 6 months\n* Myocardial infarction within past 6 months or unstable angina\n* Severe lung disease (on supplemental oxygen or frequently use rescue inhalers)\n* Participants with non-compressible vessels (ABI \\> 1.40)\n* Habitual exercise (30 minutes of continuous activity on 3 or more days per week)\n* Current tobacco smoker or use of nicotine-containing products\n* Pregnant or nursing women\n* History or ankle reconstruction or surgery Recent history (\\\u003C1 year) of injuries to the ankle, Achilles tendon, or feet\n* History of rheumatoid arthritis or other degenerative joint disease\n* Major medical illness treatment during the prior 12 months\n* Uncontrolled hypertension\n* Uncontrolled diabetes\n* Inability to walk on a treadmill at a slow pace (1.0 mile\u002Fhour)",{"count":85,"type":21},24,[24],"The goal of this clinical trial is to assess the effects of passive calf muscle stretching in patients diagnosed with peripheral artery disease (PAD). The main question it aims to answer are:\n\n1. To determine if daily calf muscle stretching at home improves calf muscle and vascular health.\n2. To determine if daily calf muscle stretching at home improves walking performance.\n\nParticipants will use inflatable ankle splints for 30 minutes a day, 5 days a week for 4-weeks on both days and 4-weeks of no stretching.",[27,28],[90],"Endothelial dysfunction","2025-07-28",{"date":93,"type":38},"2025-07-31",{"date":95,"type":38},"2024-04-01",{"date":97,"type":21},"2027-07",{"name":99,"class":45},"Penn State University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100550539","exercise-training-study-of-patients-with-claudicatio-intermittens-100550539","NCT06448390","Exercise Training Study of Patients With Claudicatio Intermittens","Randomized Clinical Trial on the Effects of Home-based Five Plus Exercise Training","Inclusion Criteria:\n\n1. Pain in the calves after 300 m, or less measured on a treadmill\n2. Stable symptoms last 6 months or more\n3. The pain must be gone within 5 minutes after the patients stop walking\n4. Ankle-Brachial index at 0.7 or lower at rest\n5. Using statins and antiplatelet drugs since at least 3 months\n6. age\\> 18 years\n7. Signed consent\n\nExclusion Criteria:\n\n1. pain in the hips or elsewhere outside the calves while walking\n2. Remaining pain more than 5 minutes after stopped walking.\n3. Impossible to compress the arteries while measruing ABI or ABI lower than 0.4\n4. Use of statins and antiplatelet drugs less than 3 months\n5. symptoms less than 6 months\n6. Diabetes measured with HbA1c being over 48 mmol\u002Fmol (6%)\n7. Revascularisation the last 6 months\n8. Pain in the calves after longer than 300 m measured on a treadmill\n9. Reduced mobility in the ankles\n10. Reduced physical ability to perform a test on a treadmill.\n11. Age less than 18 years\n12. General conditions that impairs the ability to take part in a training study including Obesity, KOLS, heart disease, arthrosis, inflammatory joint diseases .\n13. No Signed consent",{"count":108,"type":21},100,[24],"The aim of the study is to evaluate whether walking capacity in patients with intermittent claudication is improved more by home-based 5+ exercise training than by current recommendations of daily walking.",[28],"2025-06-05",{"date":114,"type":38},"2025-06-06",{"date":116,"type":38},"2024-01-01",{"date":118,"type":21},"2025-12-31",{"name":120,"class":45},"Norwegian University of Science and Technology",14,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":144,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100331368","additional-hyperbaric-oxygen-after-lower-extremity-amputation-100331368","NCT03594344","Additional Hyperbaric Oxygen After Lower Extremity Amputation","Additional Hyperbaric Oxygen After Lower Extremity Amputation - A Randomized Controlled Trial","AHOLEA","Inclusion Criteria:\n\n* Lower extremity amputation because of chronic wound, osteomyelitis, ischemia, necrosis.\n* Fit to receive hyperbaric oxygen therapy determined by an anesthesiologist\u002FHyperbaric Medicine Physician.\n* Able to cooperate and follow up appointments\n* Included within 7 days after final surgery\n\nExclusion Criteria:\n\n* Not fulfilling inclusion criteria\n* Pregnancy\n* Dementia","90 Years",{"count":132,"type":21},120,[24],"This study evaluates the effect of additional hyperbaric oxygen therapy after lower extremity amputation. The patients will be randomized after amputation to either a treatment group receiving hyperbaric oxygen therapy, or control group.",[136,28,137,138,139,140,141,142,143],"Diabetes Mellitus","Critical Limb Ischemia","Osteomyelitis","Amputation","Lower Extremity Ulcer","Diabetic Angiopathy","Diabetic Neuropathies","Diabetic Foot",[145,146,147,148,149],"Diabetic foot","Diabetes","Lower extremity amputation","Hyperbaric oxygen therapy","HBOT","2025-03-25",{"date":152,"type":38},"2025-03-30",{"date":154,"type":38},"2018-07-04",{"date":156,"type":21},"2026-12-31",{"name":158,"class":45},"Oslo University Hospital",2,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":176,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":46},"100522426","framed-infrainguinal-venous-bypass-versus-conventional-autologous-bypass-trial-100522426","NCT06082466","FRAMED Infrainguinal Venous Bypass Versus Conventional Autologous Bypass Trial","Framed IVB","Inclusion Criteria\n\n* Age at least 18 years\n* Informed consent form with signature\n* Rutherford Category 3 (\\\u003C200m) or chronic critical ischemia (Rutherford Category 4-6)\n* Assured inflow and recipient artery.\n\nExclusion Criteria\n\n* Pregnant or breastfeeding women\n* Active infection or sepsis\n* Acute ischemia\n* Endovascular procedure in the region to be treated.\n* Vein with outer diameter \\\u003C3.5 mm or \\>8 mm under pressure.\n* Spliced Veins.\n* Known allergy to the cobalt-chromium alloy (ASTM 1058) or its components (Cobalt-Chromium-Iron-Nickel-Molybdenum).\n* Vasculitis\n* Coagulopathy\n* Radiation therapy near the anastomosis",{"count":168,"type":21},110,[24],"The purpose of this clinical trial is to analyze patency after autologous infrainguinal bypass surgery in patients receiving a venous conduit versus a covered venous conduit.",[172,173,174,175,28],"Peripheral Arterial Occlusive Disease","Femoropopliteal Artery Occlusion","Femoropopliteal Stenosis","Critical Limb-Threatening Ischemia",[177,178,179],"Extraluminal Bypass Stenting","Autologous Vein Graft","Bypass Extremity Graft","2023-11-20",{"date":182,"type":38},"2023-11-21",{"date":184,"type":38},"2023-09-11",{"date":186,"type":21},"2027-09",{"name":188,"class":45},"Paracelsus Medical University"]